Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03540771 · ClinicalTrials.gov registry record · NA

Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)

A NA study, sponsored by Albert Einstein Healthcare Network.

Completed
Registry status
NA
Development phase
1,494
Enrollment target

NCT03540771 is a NA study that has completed, run by Albert Einstein Healthcare Network. The registered enrollment target is 1,494 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03540771, a NA study, has completed, sponsored by Albert Einstein Healthcare Network.

COMPLETED
Registry status
NA
Development phase
1,494 participants
Enrollment target

Study Summary

This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-Hep (Functional Assessment of Cancer Therapy- Hepatobiliary). Primary Hypothesis: Compared to consultative PC, the trained hepatologist-led PC for ESLD patients will show superior primary outcome. In the event of nonsignificant superiority, the trained hepatologist-led PC led will show non-inferiority (NI) by ruling out a 4-point reduction (NI margin) in mean of the primary outcome as compared to the consultative PC. Power: The study has 83.2% power to detect minimal clinically important difference (MCID) of 9 points in mean of the primary outcome between the two randomized arms. We have 79.2% power for the noninferiority hypothesis, under assumption that the trained hepatologist-led PC arm performs better than the consultative PC arm by half of the above MCID. Setting: 19 Clinical Centers across US are recruited to participate in this study. Qualitative nested study will interview patients, caregivers and providers to assess their experiences with participating in the palliative care trial.

Interventions

  • OTHER Palliative Care

Trial Details

FieldValue
Enrollment Target 1,494 participants
Start Date 2019-01-30
Est. Completion 2025-08-30
Phase NA

Sponsor

Albert Einstein Healthcare Network

48 total trials

What the Registry Record Tells You About NCT03540771

The ClinicalTrials.gov registry entry for NCT03540771 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein Healthcare Network, which has 48 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Palliative Care is the first listed.

NCT03540771 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03540771 about?

NCT03540771 is a clinical study titled "Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)". This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC interventi...

What is the current status of trial NCT03540771?

This trial is currently completed. It is a NA study. The enrollment target is 1,494 participants. The study started on 2019-01-30. Estimated completion is 2025-08-30.

What interventions are being tested in trial NCT03540771?

The interventions under investigation include: Palliative Care (OTHER).

Who is sponsoring clinical trial NCT03540771?

This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.